Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 35, Issue 6, Pages 811–818
http://dx.doi.org/10.1155/2013/369784
Clinical Study

Interleukin 18 as a Marker of Chronic Nephropathy in Children after Anticancer Treatment

Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, 91-738 Łódź, Poland

Received 13 August 2013; Revised 10 October 2013; Accepted 25 October 2013

Academic Editor: Natacha Turck

Copyright © 2013 Małgorzata Zubowska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. M. Geenen, M. C. Cardous-Ubbink, L. C. M. Kremer et al., “Medical assessment of adverse health outcomes in long-term survivors of childhood cancer,” Journal of the American Medical Association, vol. 297, no. 24, pp. 2705–2715, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. D. A. Mulrooney, D. C. Dover, S. Li et al., “Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia: a report from the Childhood Cancer Survivor Study,” Cancer, vol. 112, no. 9, pp. 2071–2079, 2008. View at Publisher · View at Google Scholar
  3. B. A. Kurt, V. G. Nolan, K. K. Ness et al., “Hospitalization rates among survivors of childhood cancer in the childhood cancer survivor study cohort,” Pediatric Blood & Cancer, vol. 59, no. 1, pp. 126–132, 2012. View at Publisher · View at Google Scholar
  4. B. S. Lee, J. H. Lee, H. G. Kang et al., “Ifosfamide nephrotoxicity in pediatric cancer patients,” Pediatric Nephrology, vol. 16, no. 10, pp. 796–799, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Rossi, J. Pleyer, P. Schäfers et al., “Developement of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients,” Medical and Pediatric Oncology, vol. 32, no. 3, pp. 177–182, 1999. View at Google Scholar
  6. R. Skinner, I. M. Sharkey, A. D. J. Pearson, and A. W. Craft, “Ifosfamide, mesna, and nephrotoxicity in children,” Journal of Clinical Oncology, vol. 11, no. 1, pp. 173–190, 1993. View at Google Scholar · View at Scopus
  7. R. Skinner, S. J. Cotterill, and M. C. G. Stevens, “Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study,” British Journal of Cancer, vol. 82, no. 10, pp. 1636–1645, 2000. View at Google Scholar · View at Scopus
  8. R. Skinner, A. D. J. Pearson, M. W. English et al., “Risk factors for ifosfamide nephrotoxicity in children,” The Lancet, vol. 348, no. 9027, pp. 578–580, 1996. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Skinner, A. D. J. Pearson, L. Price, K. Cunningham, and A. W. Craft, “Hypophosphataemic rickets after ifosfamide treatment in children,” British Medical Journal, vol. 298, no. 6687, pp. 1560–1561, 1989. View at Google Scholar · View at Scopus
  10. S. L. Knijnenburg, M. W. Jaspers, H. J. van der Pal et al., “Renal dysfunction and elevated blood pressure in long-term childhood cancer survivors,” Clinical Journal of the American Society of Nephrology, vol. 7, no. 9, pp. 1416–1427, 2012. View at Publisher · View at Google Scholar
  11. R. Skinner, A. Parry, L. Price, M. Cole, A. W. Craft, and A. D. J. Pearson, “Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose,” Pediatric Blood and Cancer, vol. 54, no. 7, pp. 983–989, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. O. Oberlin, O. Fawaz, A. Rey et al., “Long-term evaluation of ifosfamide-related nephrotoxicity in children,” Journal of Clinical Oncology, vol. 27, no. 32, pp. 5350–5355, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Skinner, A. Parry, L. Price, M. Cole, A. W. Craft, and A. D. J. Pearson, “Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors,” European Journal of Cancer, vol. 45, no. 18, pp. 3213–3219, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. K. K. Washburn, M. Zappitelli, A. A. Arikan et al., “Urinary interleukin-18 is an acute kidney injury biomarker in critically ill children,” Nephrology Dialysis Transplantation, vol. 23, no. 2, pp. 566–572, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. M. H. Rosner, “Urinary biomarkers for the detection of renal injury,” Advances in Clinical Chemistry, vol. 49, pp. 73–97, 2009. View at Google Scholar · View at Scopus
  16. E. Ho, A. Fard, and A. Maisel, “Evolving use of biomarkers for kidney injury in acute care settings,” Current Opinion in Critical Care, vol. 16, no. 5, pp. 399–407, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. X. L. Liang, S. X. Liu, Y. H. Chen et al., “Combination of urinary kidney injury molecule-1 and interleukin-18 as early biomarker for the diagnosis and progressive assessment of acute kidney injury following cardiopulmonary bypass surgery: a prospective nested casecontrol study,” Biomarkers, vol. 15, no. 4, pp. 332–339, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. J. L. Koyner, V. S. Vaidya, M. R. Bennet et al., “Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 12, pp. 2154–2165, 2010. View at Publisher · View at Google Scholar
  19. C. R. Parikh, J. C. Lu, S. G. Coca, and P. Devarajan, “Tubular proteinuria in acute kidney injury: a critical evaluation of current status and future promise,” Annals of Clinical Biochemistry, vol. 47, no. 4, pp. 301–312, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. B. C. Widemann, F. M. Balis, A. Kim et al., “Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome,” Journal of Clinical Oncology, vol. 28, no. 25, pp. 3979–3986, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Darmon, I. Guichard, F. Vincent, B. Schlemmer, and L. Azoulay, “Prognostic significance of acute renal injury in acute tumor lysis syndrome,” Leukemia and Lymphoma, vol. 51, no. 2, pp. 221–227, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. K. A. Janeway and H. E. Grier, “Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects,” The Lancet Oncology, vol. 11, no. 7, pp. 670–678, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. M. S. Ashraf, J. Brady, F. Breatnach, P. F. Deasy, and A. O'Meara, “Ifosfamide nephrotoxicity in paediatric cancer patients,” European Journal of Pediatrics, vol. 153, no. 2, pp. 90–94, 1994. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Zielińska, M. Zubowska, and K. Misiura, “Role of GSTM1, GSTP1, and GSTT1 gene polymorphism in ifosfamide metabolism affecting neurotoxicity and nephrotoxicity in children,” Journal of Pediatric Hematology/Oncology, vol. 27, no. 11, pp. 582–589, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. W. Stöhr, M. Paulides, S. Bielack et al., “Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the late effects surveillance system,” Pediatric Blood and Cancer, vol. 48, no. 4, pp. 447–452, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Skinner, “Chronic ifosfamide nephrotoxicity in children,” Medical and Pediatric Oncology, vol. 41, no. 3, pp. 190–197, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. N. M. Marina, C. A. Poquette, A. M. Cain, D. Jones, C. B. Pratt, and W. H. Meyer, “Comparative renal tubular toxicity of chemotherapy regimens including ifosfamide in patients with newly diagnosed sarcomas,” Journal of Pediatric Hematology/Oncology, vol. 22, no. 2, pp. 112–118, 2000. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Arjmandi-Rafsanjani, N. Hooman, and P. Vosoug, “Renal function in late survivors of Iranian children with cancer: single centre experience,” Indian Journal of Cancer, vol. 45, no. 4, pp. 154–157, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Camano, A. Lazaro, E. Moreno-Gordaliza et al., “Cilastatin attenuates cisplatin-induced proximal tubular cell damage,” Journal of Pharmacology and Experimental Therapeutics, vol. 334, no. 2, pp. 419–429, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Moore, R. Bellomo, and A. Nichol, “Biomarkers of acute kidney injury in anesthesia, intensive care and major surgery: from the bench to clinical research to clinical practice,” Minerva Anestesiologica, vol. 76, no. 6, pp. 425–440, 2010. View at Google Scholar · View at Scopus
  31. M. Che, B. Xie, S. Xue et al., “Clinical usefulness of novel biomarkers for the detection of acute kidney injury following elective cardiac surgery,” Nephron Clinical Practice, vol. 115, no. 1, pp. c66–c72, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. R. Oberbauer, “Biomarkers—a potential route for improved diagnosis and management of ongoing renal damage,” Transplantation Proceedings, vol. 40, no. 10, pp. S44–S47, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. P. Devarajan, “The future of pediatric acute kidney injury management-biomarkers,” Seminars in Nephrology, vol. 28, no. 5, pp. 493–498, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. R. J. Trof, F. Di Maggio, J. Leemreis, and A. B. J. Groeneveld, “Biomarkers of acute renal injury and renal failure,” Shock, vol. 26, no. 3, pp. 245–253, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. E. D. Siew, T. A. Ikizler, T. Gebretsadik et al., “Elevated urinary IL-18 levels at the time of ICU admission predict adverse clinical outcomes,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 8, pp. 1497–1505, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Wu, M. L. Craft, P. Wang et al., “IL-18 contributes to renal damage after ischemia-reperfusion,” Journal of the American Society of Nephrology, vol. 19, no. 12, pp. 2331–2341, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. C. L. Edelstein, “Biomarkers of acute kidney injury,” Advances in Chronic Kidney Disease, vol. 15, no. 3, pp. 222–234, 2008. View at Publisher · View at Google Scholar · View at Scopus